Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Shield provides the headline results from the reanalysis of the AEGIS-H2H study.

6 Aug 2020

Shield Therapeutics plc, provides the headline results from the reanalysis of the AEGIS-H2H study. For further details click here.

Back to news